Cargando…

Proton Pump Inhibitors Should be Used with Caution in Critically Ill Patients to Prevent the Risk of Clostridium difficile Infection

Detalles Bibliográficos
Autores principales:	Min, Jung Hwa, Kim, You Sun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933404/ https://www.ncbi.nlm.nih.gov/pubmed/27377737 http://dx.doi.org/10.5009/gnl16216

Ejemplares similares

Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients
por: Barletta, Jeffrey F, et al.
Publicado: (2014)

Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients
por: Ro, Youngouk, et al.
Publicado: (2016)

Proton pump inhibitors and the incidence of Clostridium difficile on the intensive care unit
por: Whitehead, I, et al.
Publicado: (2007)

The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection
por: Tawam, Dania, et al.
Publicado: (2021)

Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection
por: Inghammar, Malin, et al.
Publicado: (2021)

QTc Prolongation in the Critically Ill: Tread with Caution!
por: Elangovan, Ashok
Publicado: (2020)

Proton pump inhibitors and 180-day mortality in the elderly after Clostridium difficile treatment
por: Bradley, Evan Stuart, et al.
Publicado: (2019)

515. Estimating the Effect of Proton Pump Inhibitor Stewardship in Reducing Clostridium difficile Transmission
por: Lofgren, Eric, et al.
Publicado: (2018)

Does Proton Pump Inhibitor Increase the Clostridium difficile Infection Risk in the Treatment and Prophylaxis of Stress Ulcers than Histanime-2 Receptor Antagonist?
por: Eun, Chang Soo
Publicado: (2017)

Clostridium difficile Infection and Proton Pump Inhibitor Use in Hospitalized Pediatric Cystic Fibrosis Patients
por: Pohl, John F., et al.
Publicado: (2011)

Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis
por: Trifan, Anca, et al.
Publicado: (2017)

Recurrence and death after Clostridium difficile infection: gender-dependant influence of proton pump inhibitor therapy
por: Dos Santos-Schaller, Ophélie, et al.
Publicado: (2016)

Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility
por: Seto, Charlie T, et al.
Publicado: (2014)

Proton Pump Inhibitors and Clostridium Difficile Infection: Are We Propagating an Already Rapidly Growing Healthcare Problem?
por: Patil, Rashmee, et al.
Publicado: (2013)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Erratum to: Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility
por: Seto, Charlie T., et al.
Publicado: (2016)

Association between Proton Pump Inhibitor Therapy and Clostridium difficile Infection: A Contemporary Systematic Review and Meta-Analysis
por: Tleyjeh, Imad M., et al.
Publicado: (2012)

Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea
por: Weiss, Karl, et al.
Publicado: (2015)

Proton-pump inhibitors should be strictly prescribed in clinic
por: Yang, Xuesong, et al.
Publicado: (2022)

Risk of Pyogenic Liver Abscess in Proton Pump Inhibitor Users: New Inventory of Proton Pump Inhibitor Induced Complications?
por: Bang, Ki Bae
Publicado: (2021)

Editorial for the Special Issue: Clostridium difficile
por: Grześkowiak, Łukasz M.
Publicado: (2021)

Proton Pump Inhibitor-associated Mucosal Change
por: Kato, Mototsugu, et al.
Publicado: (2017)

Proton pump inhibitors in the COVID-19 pandemic()
por: Sebastián Domingo, Juan J.
Publicado: (2021)

Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention
por: Song, Jung Hoon, et al.
Publicado: (2019)

Clinical impact and outcome of clostridium non-difficile infection in critically ill patients
por: Rutter, K, et al.
Publicado: (2015)

Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness
por: Brett, Stephen
Publicado: (2005)

Caution
Publicado: (1889)

Diarrhoea in the critically ill is common, associated with poor outcome, and rarely due to Clostridium difficile
por: Tirlapur, Nikhil, et al.
Publicado: (2016)

P029: Regional differences in Clostridium difficile infections (CDI) in relation to fluoroquinolone (FQ) and proton pump inhibitor (PPI) use, Finland, 2008-2011
por: Kanerva, M, et al.
Publicado: (2013)

The Risk Factors of Clostridium difficile Colitis in Colorectal Surgery
por: Yoo, Seung Jin
Publicado: (2010)

Risk Factors for Delayed Recurrence of Clostridium difficile Infection
por: Kim, Ji Won
Publicado: (2014)

The Challenging Conundrum of Diagnosing and Managing Clostridium difficile Infection
por: Gerding, Dale N., et al.
Publicado: (2017)

Proton Pump Inhibitor-Responsive Esophageal Eosinophilia: Controversies and Its Clinical Implications
por: Shin, Cheol Min, et al.
Publicado: (2016)

Can proton pump inhibitors cause intestinal inflammation in children?
por: Kang, Ben
Publicado: (2019)

H(2) antagonists, proton pump inhibitors and COVID-19
por: Hirota, Kazuyoshi
Publicado: (2022)

The Complex Interaction between Proton Pump Inhibitors and Cancer Treatment
por: Chen, Hao, et al.
Publicado: (2023)

PARP inhibitors, use early in the first-line maintenance therapy setting but with caution
por: Giudice, Elena, et al.
Publicado: (2023)

Low level ALK FISH positive results should be approached with caution and confirmed by an orthogonal method
por: Toruner, Gokce A.
Publicado: (2023)

2389. Assessing the Time Course of Proton Pump Inhibitor Use and Clostridioides difficile Infection
por: Panagos, Katherine, et al.
Publicado: (2019)

Clostridium difficile-associated diarrhea following the therapy with antibiotic and proton pump inhibitors in a 77-year-old man with several comorbidities: A case report
por: Lv, Xiaoqun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pg42t3s7npppj716f8fnmf9dci